Literature DB >> 7794080

Colon cancer cells that are not growth inhibited by TGF-beta lack functional type I and type II TGF-beta receptors.

S L MacKay1, L R Yaswen, R W Tarnuzzer, L L Moldawer, K I Bland, E M Copeland, G S Schultz.   

Abstract

OBJECTIVE: The authors determined the molecular mechanisms for the failure of transforming growth factor-beta (TGF-beta) to inhibit the growth of SW1116 and SW48 colon cancer cell lines.
BACKGROUND: Transforming growth factor-beta is a bifunctional regulator of cell growth that typically stimulates proliferation of mesenchymal cells, but inhibits proliferation of normal epithelial cells. In the colon, TGF-beta appears to arrest proliferation of enterocytes as they leave the intestinal crypt and move to the villus tip. Transforming growth factor-beta actions are mediated by binding to heteromeric complexes of type I and type II TGF-beta receptors. Loss of TGF-beta responsiveness may contribute to uncontrolled cell growth and cancer.
METHODS: The effects of TGF-beta 1 on DNA synthesis were measured by incorporation of tritiated thymidine into DNA of cultures of moderately differentiated adenocarcinoma (SW48) and poorly differentiated adenocarcinoma (SW1116) colon cell lines and a mink lung epithelial cell line (CCL-64). The effects of TGF-beta on the expression of c-myc, TGF-alpha, and TGF-beta in SW48 cells, SW1116 cells, and CCL-64 cells (c-myc only) were measured by Northern blot analysis. Expression of TGF-beta receptors in the cell lines was measured using competitive binding assays, receptor affinity labelling techniques, and reverse transcriptase-polymerase chain reaction.
RESULTS: Incubation with TGF-beta 1 (50 ng/mL) did not decrease serum-stimulated uptake of [3H]-thymidine into actively growing cultures of SW48 or SW1116 cells, but suppressed DNA synthesis of actively growing CCL-64 cells by 90%. Similarly, incubation with TGF-beta 1 (12 ng/mL) for 4 hours did not substantially alter the mRNA levels of c-myc, TGF-alpha, and TGF-beta 1 in either colon tumor cell line, although levels of c-myc mRNA in CCL-64 cells were reduced by TGF-beta 1 treatment. Competitive displacement of [125I]-TGF-beta 1 binding detected high levels (16,500 TGF-beta receptors per cell) of specific, high-affinity (200 pmol/L half-displacement) TGF-beta receptors on CCL-64 cells. In marked contrast, very low levels of TGF-beta 1 binding to SW1116 cells (250 receptors per cell) and SW48 cells (260 receptors per cell) were detected. Autoradiograms of CCL-64 cells affinity labelled with [125I]TGF-beta 1 revealed the presence of type I, type II, and type III TGF-beta receptors. No TGF-beta receptors were identified on SW1116 cells, and only very low levels of the nonsignaling type III TGF-beta receptors were detected on SW48 cells. Reverse transcriptase-polymerase chain reaction amplification detected mRNAs for type I, type II, and type III TGF-beta receptors in CCL-64 cells. SW48 cells, and SW1116 cells.
CONCLUSIONS: These results suggest that the lack of growth inhibition by TGF-beta in SW48 and SW1116 colon cancer cells may be caused by a lack of expression of functional TGF-beta receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794080      PMCID: PMC1234710          DOI: 10.1097/00000658-199506000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor.

Authors:  R Ebner; R H Chen; L Shum; S Lawler; T F Zioncheck; A Lee; A R Lopez; R Derynck
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

3.  Growth factors and corneal endothelial cells: I. Stimulation of bovine corneal endothelial cell DNA synthesis by defined growth factors.

Authors:  P G Woost; M M Jumblatt; R A Eiferman; G S Schultz
Journal:  Cornea       Date:  1992-01       Impact factor: 2.651

4.  TGF beta signals through a heteromeric protein kinase receptor complex.

Authors:  J L Wrana; L Attisano; J Cárcamo; A Zentella; J Doody; M Laiho; X F Wang; J Massagué
Journal:  Cell       Date:  1992-12-11       Impact factor: 41.582

5.  The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand.

Authors:  A Moustakas; H Y Lin; Y I Henis; J Plamondon; M D O'Connor-McCourt; H F Lodish
Journal:  J Biol Chem       Date:  1993-10-25       Impact factor: 5.157

6.  Betaglycan presents ligand to the TGF beta signaling receptor.

Authors:  F López-Casillas; J L Wrana; J Massagué
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

7.  Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes.

Authors:  M Reiss; V F Vellucci; Z L Zhou
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

8.  Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta.

Authors:  K Park; S J Kim; Y J Bang; J G Park; N K Kim; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

9.  Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor.

Authors:  P Franzén; P ten Dijke; H Ichijo; H Yamashita; P Schulz; C H Heldin; K Miyazono
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

10.  Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors.

Authors:  L Attisano; J Cárcamo; F Ventura; F M Weis; J Massagué; J L Wrana
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

View more
  1 in total

1.  Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype.

Authors:  S L MacKay; T Auffenberg; C L Tannahill; R Ksontini; M D Josephs; M Nowak; L L Moldawer; E M Copeland
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.